Big pharma, Partnering, Pharma

Boehringer Ingelheim and Vanderbilt partner for RAS inhibitors for cancer

Posted on 15 January 2015

Tags: , ,

Boehringer Ingelheim has established a research alliance with Vanderbilt University and the cancer drug discovery laboratory of Professor Stephen W. Fesik, Ph.D., the Orrin H. Ingram, II Chair in Cancer Research and Professor of Biochemistry, Pharmacology, and Chemistry.

The aim of the new collaboration is the research and development of small molecule inhibitors of oncogenic Ras for the treatment of cancer.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
  • CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

 

Under the terms of the agreement, the research capabilities of Vanderbilt University and Boehringer Ingelheim will be brought together in a multi-year research programme focusing on the development of small molecule inhibitors of Ras.

Further details of the agreement are not disclosed.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio

Print Friendly, PDF & Email

Leave a Reply